Medical management of pancreatic neuroendocrine tumors (Q37009032)

17 August 2017

1 reference

title

Medical management of pancreatic neuroendocrine tumors (English)

1 reference

17 August 2017

4

Charles Erlichman

1 reference

17 August 2017

Thierry Delaunoit

1

1 reference

17 August 2017

Florence Neczyporenko

series ordinal

2

1 reference

17 August 2017

Joseph Rubin

series ordinal

3

1 reference

17 August 2017

Timothy J Hobday

series ordinal

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

19 November 2007

1 reference

The American Journal of Gastroenterology

17 August 2017

1 reference

17 August 2017

103

1 reference

17 August 2017

2

1 reference

17 August 2017

475-83; quiz 484

1 reference

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Surgical treatment of non-functioning pancreatic islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Dendritic cell based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Dendritic cell-based vaccination in solid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Endocrine tumours of the pancreas: review and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Pancreatic somatostatinoma: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01643.X

10.1111/J.1572-0241.2007.01643.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference